Literature DB >> 8648562

Twenty-four hour urinary excretion of 6-hydroxymelatonin sulfate in Down syndrome subjects.

R J Reiter1, L Barlow-Walden, B Poeggeler, S M Heiden, R J Clayton.   

Abstract

Because of the overexpression of the enzyme superoxide dismutase, individuals with Down syndrome (DS) are believed to suffer from increased oxidative stress as a result of the excessive production of oxygen-based free radicals; their exposure to higher than normal free radical production may account in part for signs of premature aging, early onset of cataracts, and of Alzheimer's disease. Free radicals are normally neutralized by free radical scavengers and other antioxidants. The pineal hormone melatonin is a potent scavenger of both the hydroxyl and peroxyl radicals, both of which are highly toxic, and a stimulator of the antioxidative enzyme glutathione peroxidase. Considering this, we deemed it important to define the day/night rhythm and levels of melatonin production in DS subjects. To do this, we assessed the urinary excretion of the chief melatonin metabolite, 6-hydroxymelatonin sulfate, throughout a 24 hr period in DS subjects; comparisons were made with the metabolite levels in the urine of non-Down siblings and parents of the DS subjects. All 8 non-Down subjects exhibited what was classified as normal urinary excretion of 6-hydroxymelatonin sulfate with the usual low daytime and high night-time levels of the melatonin metabolite. Of 12 DS subjects studied, 10 exhibited the normal day/night rhythm in urinary 6-hydroxymelatonin sulfate levels; 2 subjects were devoid of a rhythm. However, when all the data from each group were averaged, there were no noticeable differences in the absolute levels or 24 hr variations in urinary 6-hydroxymelatonin sulfate excretion between DS and non-Down subjects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648562     DOI: 10.1111/j.1600-079x.1996.tb00238.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  7 in total

1.  Abnormal circadian rhythm of melatonin in Smith-Magenis syndrome patients with RAI1 point mutations.

Authors:  Philip M Boone; Russel J Reiter; Daniel G Glaze; Dun-Xian Tan; James R Lupski; Lorraine Potocki
Journal:  Am J Med Genet A       Date:  2011-07-07       Impact factor: 2.802

2.  Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome.

Authors:  L Potocki; D Glaze; D X Tan; S S Park; C D Kashork; L G Shaffer; R J Reiter; J R Lupski
Journal:  J Med Genet       Date:  2000-06       Impact factor: 6.318

3.  Aging and oxygen toxicity: Relation to changes in melatonin.

Authors:  R J Reiter
Journal:  Age (Omaha)       Date:  1997-10

4.  Diurnal variations in salivary protein carbonyl levels in normal and cognitively impaired human subjects.

Authors:  Haixiang Su; Mervyn Gornitsky; Guoyan Geng; Ana M Velly; Howard Chertkow; Hyman M Schipper
Journal:  Age (Dordr)       Date:  2008-01-04

Review 5.  Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives.

Authors:  Sylvie Tordjman; Imen Najjar; Eric Bellissant; George M Anderson; Marianne Barburoth; David Cohen; Nemat Jaafari; Olivier Schischmanoff; Rémi Fagard; Enas Lagdas; Solenn Kermarrec; Sophie Ribardiere; Michel Botbol; Claire Fougerou; Guillaume Bronsard; Julie Vernay-Leconte
Journal:  Int J Mol Sci       Date:  2013-10-14       Impact factor: 5.923

6.  Young children with Down syndrome show normal development of circadian rhythms, but poor sleep efficiency: a cross-sectional study across the first 60 months of life.

Authors:  Fabian Fernandez; Casandra C Nyhuis; Payal Anand; Bianca I Demara; Norman F Ruby; Goffredina Spanò; Caron Clark; Jamie O Edgin
Journal:  Sleep Med       Date:  2017-02-10       Impact factor: 3.492

7.  Melatonin as an immunomodulator in children with Down syndrome.

Authors:  Dean Huggard; Lynne Kelly; Amy Worrall; Eleanor Gallagher; Lida Fallah; Lucas Lu Yoo; Fiona McGrane; Niamh Lagan; Edna Roche; Joanne Balfe; Derek G Doherty; Eleanor J Molloy
Journal:  Pediatr Res       Date:  2021-08-16       Impact factor: 3.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.